An in vivo study investigating the RANK pathway and CDK4/6 inhibition indicated that RANK pathway inhibition can modulate immune responses, thereby influencing the tumor microenvironment and potentially synergizing with the antitumor activity of CDK4/6 inhibitors [21]. Here, TNFRSF11A is linked to neoplasm.